Matches in Wikidata for { <http://www.wikidata.org/entity/Q90466613> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q90466613 description "article scientifique publié en 2018" @default.
- Q90466613 description "artículu científicu espublizáu en xunetu de 2018" @default.
- Q90466613 description "scientific article published on 25 July 2018" @default.
- Q90466613 description "wetenschappelijk artikel" @default.
- Q90466613 description "наукова стаття, опублікована в липні 2018" @default.
- Q90466613 name "Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer" @default.
- Q90466613 name "Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer" @default.
- Q90466613 type Item @default.
- Q90466613 label "Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer" @default.
- Q90466613 label "Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer" @default.
- Q90466613 prefLabel "Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer" @default.
- Q90466613 prefLabel "Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer" @default.
- Q90466613 P1433 Q90466613-C351DC71-ED82-446E-B688-29655425A35D @default.
- Q90466613 P1476 Q90466613-46B27635-7276-4997-8D5F-1E3EAD13B1BC @default.
- Q90466613 P2093 Q90466613-09AE940A-4D32-493A-8D79-7B52AE588A4C @default.
- Q90466613 P2093 Q90466613-25881697-3F8E-4E4C-BCBB-8B701A3C8CA9 @default.
- Q90466613 P2093 Q90466613-2A63CF48-0D70-4E2F-BF64-0A085D4C9B39 @default.
- Q90466613 P2093 Q90466613-36712AA9-D0A3-4299-91E4-3F3E515ECEF9 @default.
- Q90466613 P2093 Q90466613-6ADED606-78BD-405F-BF63-E63024684034 @default.
- Q90466613 P2093 Q90466613-B666ED72-5F07-476B-B908-69099AFA78AB @default.
- Q90466613 P304 Q90466613-FD61068D-AA79-4223-91FB-C1EF0432CE12 @default.
- Q90466613 P31 Q90466613-CD496AF8-B3E9-437F-B189-40E18D3EB511 @default.
- Q90466613 P356 Q90466613-3B0D1697-73CB-497C-8686-E2717558237D @default.
- Q90466613 P433 Q90466613-82A65A7A-9BD4-4342-B7B3-350B33B99507 @default.
- Q90466613 P478 Q90466613-39205A18-B3A5-4C5C-8DC0-A3EC36F35E94 @default.
- Q90466613 P577 Q90466613-6792F16C-1F27-47AD-95A9-60F786BD9D15 @default.
- Q90466613 P698 Q90466613-58333F55-8C32-4265-B605-58D0ED6D7520 @default.
- Q90466613 P921 Q90466613-923712FE-E751-4886-AC5A-F1A7CB9CC3A9 @default.
- Q90466613 P356 JOP.18.00127 @default.
- Q90466613 P698 30044685 @default.
- Q90466613 P1433 Q6295683 @default.
- Q90466613 P1476 "Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer" @default.
- Q90466613 P2093 "Addie Hill" @default.
- Q90466613 P2093 "Jun Gong" @default.
- Q90466613 P2093 "Loretta Erhunmwunsee" @default.
- Q90466613 P2093 "Ravi Salgia" @default.
- Q90466613 P2093 "Rizvan Mirza" @default.
- Q90466613 P2093 "Sharon Wilczynski" @default.
- Q90466613 P304 "569-571" @default.
- Q90466613 P31 Q13442814 @default.
- Q90466613 P356 "10.1200/JOP.18.00127" @default.
- Q90466613 P433 "9" @default.
- Q90466613 P478 "14" @default.
- Q90466613 P577 "2018-07-25T00:00:00Z" @default.
- Q90466613 P698 "30044685" @default.
- Q90466613 P921 Q13896859 @default.